Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003569 · ClinicalTrials.gov registry record
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
A clinical trial, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- 2
- Enrollment target
NCT00003569: Completed study, sponsored by Roswell Park Cancer Institute.
NCT00003569 is a clinical trial that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003569 has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in treating patients with solid tumors who are receiving cisplatin and paclitaxel.
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- DRUG dimesna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 1998-03 |
What the finished NCT00003569 record still lists
NCT00003569 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00003569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003569 about?
NCT00003569 is a clinical study titled "Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells from the side effects of chemotherapy. PURPOSE: This phase I trial is studying the side effects and best dose of dim...
What is the current status of trial NCT00003569?
This trial is currently completed. The enrollment target is 2 participants. The study started on 1998-03.
What interventions are being tested in trial NCT00003569?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), dimesna (DRUG).
Who is sponsoring clinical trial NCT00003569?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia